Web27 apr. 2024 · Durham, N.C.-based BioCryst said the EMA granted BCX9250 access to the PRIME scheme, which is designed to optimize development plans and speed up evaluation so these medicines can potentially ... Web1 nov. 2024 · BCRX earnings call for the period ending September 30, 2024. Image source: The Motley Fool. BioCryst Pharmaceuticals ( BCRX 0.34%) Q3 2024 Earnings Call. Nov 01, 2024, 8:30 a.m. ET.
Why BioCryst Stock Shot Nearly 5% Higher Today
Web6 sep. 2024 · Our honoree: Dr. Helen Thackray Title: Chief research and development officer, BioCryst Pharmaceuticals The company’s focus: BioCryst is a commercial … Web4 apr. 2024 · Helen Thackray GLYC stock SEC Form 4 insiders trading. Helen has made over 9 trades of the GlycoMimetics Inc stock since 2016, ... BCRX Biocryst Pharmaceuticals Inc. Helen M. Thackray. Chief R a D Officer. Predaj: 3,125: $10.89: $34,031. 15 Dec 2024 133,275: ↗ 1 Apr 2024: BCRX Biocryst Pharmaceuticals Inc. gerard sherman
BioCryst Oral Drugs for Rare Disease Leadership
Web23 sep. 2024 · Dr. Thackray currently serves as chief medical officer and senior vice president of clinical development at GlycoMimetics, Inc., a clinical-stage biotechnology … Web10 jan. 2024 · BCX9930 is especially exciting because the clinical data we have reported so far provides confidence that we can help patients in PNH, and across many complement-mediated diseases, with this pipeline in a molecule," said Dr. Helen Thackray, chief research and development officer of BioCryst. Web19 mrt. 2024 · Dr. Thackray currently serves on the BioCryst board of directors and most recently served as chief medical officer and senior vice president of clinical development … christina milian dip it low instrumental